Isodiol International Inc.. Announces Acquisition of Strategic Investor Relationship, Inc. and Food Labs with Toba Capital LLC

Isodiol International Inc..

Isodiol International Inc.. The trade for Food Labs is valued at US$12 million, which comprises US$5 million cash on its balance sheet, and also brings the appointment of a new Chief Executive Officer and Chairman of the Board of Directors of Isodiol. 

Food Labs is a brand-focused innovator of hemp- and cannabis-based consumer products with a flagship line of full spectrum, hemp-oil established health and wellness products.   The Food Labs management group has extensive experience bringing consumer products to mass retail, including in the ready-to-drink beverage marketplace.   Leading the Food Labs team is Michael Cancelleri who also will become Chief Executive Officer and Chairman of the Board of Directors of Isodiol upon closing the transaction.  

“Isodiol is the pioneer of numerous firsts in CBD and other hemp extract ingredients which it is the obvious partner for Food Labs and our mutual growth in customer markets,” said Mr. Cancelleri.   “I personally look forward to bringing my experience in bulk retail investments to Isodiol and helping to form Isodiol’s growth from the bulk wholesale of CBD to dominance in finished consumer goods, both as a contract manufacturer and as a new leader. ”

Food Labs’ principal financial partner is Toba Capital, LLC, a venture capital firm that was founded in late 2012 by Vinny Smith, former CEO of Quest Software.  Toba is among the largest venture capital firms in Orange County, California with over US$1 billion invested in approximately 150 companies.   A member of Isodiol’s Board of Directors will be appointed by Toba upon closing the transaction.

“As a venture capital company, Toba is dedicated to the ongoing financial and managerial support of its portfolio companies,” said Vinny Smith, Founder of Toba. “We consider the purchase of Food Labs and its seasoned management team is going to be a fantastic complement to the chances Isodiol and its team have created in this burgeoning sector. ”

“The addition of Mike and his team at Food Labs and Toba are precisely what Isodiol needs to carry our success into mainstream retail since the rest of the industry struggles to produce innovative hemp components and formulate them into quality finished goods,” said Marcos Agramont, CEO of Isodiol.   “We have been doing this for many years and in many cases figured out how to do it first.   We fully intend to continue that success into conventional retails channels. I feel convinced ceding the reigns to Mike and Toba and remaining as a resource to the company moving forward. ”

Isodiol will issue an aggregate amount of shares of its common stock to Food Labs’ shareholders in an amount equivalent to US$12,000,000, subject to Canadian Securities Exchange regulations and priced as of the market close on December 18, 2018. A 10 percent finder’s commission will be paid at the closing of this transaction.

Follow Our Corporate Upgrades On Facebook in https://www.facebook.com/IsodiolInternationalInc/, on Twitter @Isodiolintlinc, and on Instagram @isodiol.

About Isodiol International Inc..

Isodiol International Inc.. Is focused on the nutritional health benefits which are derived from hemp and is a product development, sales, marketing and distribution company of hemp-based consumer products and solutions.

Isodiol has commercialized a 99%+ pure, naturally isolated CBD, including micro-encapsulations, and nano-technology for quality consumable and topical skincare products. Most recently, the Company received approval for its CBD designated as an Active Pharmaceutical Ingredient for use in Finished Pharmaceutical Products, as was announced on April 26, 2018.

Isodiol’s growth strategy involves the development of over-the-counter and pharmaceutical drugs and continued global expansion into Latin America, Asia, and Europe.

ON BEHALF OF THE BOARD
Marcos Agramont, CEO & Director

INVESTOR RELATIONS:
Ir@isodiol.com
604-409-4409

MEDIA CONTACT:
Christopher Hussey
chussey@isodiol.com

Forward-Looking Information: This news release contains”forward-looking information” within the meaning of applicable securities laws pertaining to statements about the firm’s business, products and future the Company’s business, its product offerings and strategies for sales and marketing. Even though the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be right. Readers are cautioned not to put undue reliance on forward-looking info. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company’s products and plan will be different from those stated in this news release and the Company might not be able to carry out its business plans as anticipated. Except as required by law, the Company expressly disclaims any obligation and does not intend, to update any forward-looking statements or forward-looking information in this news release. Even though the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be right and makes no reference to adulthood based on sales reported. The statements in this news release are made as of the date of this release.

The CSE has not reviewed, approved or disapproved the content of this press release.

Published at Thu, 20 Dec 2018 20:02:01 +0000

Posted in: News

Comments are closed.